Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AZD3293

- PMLiVE

Baxter plans to file long-acting Advate in EU next year

Patients experienced a 95% reduction in bleeds

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

- PMLiVE

MedImmune partners with university on protein formulation science

Four-year partnership to research antibodies and novel proteins

- PMLiVE

AZ adds to respiratory portfolio with Actavis drugs

Follows deal to acquire Almirall’s franchise in asthma and COPD

- PMLiVE

AZ and University of Texas to collaborate on cancer research

Studies will aim to improve patient outcomes

Biogen Idec building

Biogen Idec plans phase III Alzheimer’s trial before year-end

And MS drugs drive 2014 sales          

- PMLiVE

Teva’s generic Nexium wins US approval

FDA backs copy of AstraZeneca’s heartburn drug

- PMLiVE

MedImmune partners with US National Cancer Institute

Will research immunotherapies, imaging and stem cell treatments

- PMLiVE

Clinical data sharing ‘should be the norm’, says IoM

US Institute pitches into clinical data transparency debate

EU flag

Pharma joins European Alzheimer’s research initiative

Lilly and Janssen among participants of dementia-focused IMI project

- PMLiVE

AZ signs yet another cancer immunotherapy deal

Will work with Omnis to develop viruses that target tumour cells

- PMLiVE

FDA approved 44 new drugs in 2014

AstraZeneca leads pharma success with four approvals, but Bayer had a year to forget  

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links